article thumbnail

FD-AID, LLC Announces Expansion of Services to India’s Pharmaceutical Sector

Pharma Mirror

New Delhi, India – FD-AID, LLC, a distinguished leader in pharmaceutical quality and compliance solutions, proudly announces its entry into the Indian pharmaceutical market.

article thumbnail

What Does Google’s Move to Responsive Search Ads for Paid Search Mean for Pharma?

Intouch Solutions

Let’s talk about what that means for pharma marketers! Why Pharma Marketers Should Care About RSAs RSAs are a text ad format that requires an increased number of headline and description line variations than ETAs require. Among the concerns that pharma marketers face: The RSA ad format will be new to most MLR reviewers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog

The FDA compliance data, sorted by category, shows there were 159 Warning Letters issued to drug manufacturers or sponsors during 2023, with 161 issued in calendar year 2022. FDA stated that the firm received 96 U.S. Summaries of the most striking recently released Warning Letters are included below. Dextrum Laboratories Inc.

article thumbnail

FDA Flips It and Reverses It: FDA Withdraws HHS Withdrawal of UDI Guidance

FDA Law Blog

Koblitz — While typically, FDA is responsible for setting forth its own agenda and enforcing compliance with its own regulations, the Trump Administration’s HHS, on its way out the door in late 2020 , took the unusual steps of withdrawing an important FDA Compliance Policy Guide, “Marketed Unapproved Drugs – Compliance Policy Guide Sec.